Structural insights and biomedical potential of IgNAR scaffolds from sharks by Zielonka, Stefan et al.
This article was downloaded by: [University of Aberdeen]
On: 26 January 2015, At: 03:07
Publisher: Taylor & Francis
Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House,
37-41 Mortimer Street, London W1T 3JH, UK
Click for updates
mAbs
Publication details, including instructions for authors and subscription information:
http://www.tandfonline.com/loi/kmab20
Structural insights and biomedical potential of IgNAR
scaffolds from sharks
Stefan Zielonkaa, Martin Emptingb, Julius Grzeschika, Doreen Könninga, Caroline J Barellec &
Harald Kolmara
a Institute for Organic Chemistry and Biochemistry; Technische Universität Darmstadt;
Darmstadt, Germany
b Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS); Department Drug Design
and Optimization; Saarland University; Saarbrücken, Germany
c Institute of Medical Science; University of Aberdeen; Aberdeen, Scotland, United Kingdom
Accepted author version posted online: 18 Dec 2014.Published online: 14 Jan 2015.
To cite this article: Stefan Zielonka, Martin Empting, Julius Grzeschik, Doreen Könning, Caroline J Barelle & Harald
Kolmar (2015) Structural insights and biomedical potential of IgNAR scaffolds from sharks, mAbs, 7:1, 15-25, DOI:
10.4161/19420862.2015.989032
To link to this article:  http://dx.doi.org/10.4161/19420862.2015.989032
PLEASE SCROLL DOWN FOR ARTICLE
Taylor & Francis makes every effort to ensure the accuracy of all the information (the “Content”) contained in
the publications on our platform. Taylor & Francis, our agents, and our licensors make no representations or
warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Versions
of published Taylor & Francis and Routledge Open articles and Taylor & Francis and Routledge Open Select
articles posted to institutional or subject repositories or any other third-party website are without warranty
from Taylor & Francis of any kind, either expressed or implied, including, but not limited to, warranties of
merchantability, fitness for a particular purpose, or non-infringement. Any opinions and views expressed in this
article are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The
accuracy of the Content should not be relied upon and should be independently verified with primary sources
of information. Taylor & Francis shall not be liable for any losses, actions, claims, proceedings, demands,
costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in
connection with, in relation to or arising out of the use of the Content.
 
This article may be used for research, teaching, and private study purposes. Terms & Conditions of access and
use can be found at http://www.tandfonline.com/page/terms-and-conditions
 
It is essential that you check the license status of any given Open and Open Select article to confirm
conditions of access and use.
Structural insights and biomedical potential
of IgNAR scaffolds from sharks
Stefan Zielonka1,y, Martin Empting2,y, Julius Grzeschik1, Doreen K€onning1, Caroline J Barelle3, and Harald Kolmar1,*
1Institute for Organic Chemistry and Biochemistry; Technische Universit€at Darmstadt; Darmstadt, Germany; 2Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS);
Department Drug Design and Optimization; Saarland University; Saarbr€ucken, Germany; 3Institute of Medical Science; University of Aberdeen; Aberdeen, Scotland, United Kingdom
yThese authors contributed equally to this paper.
Keywords: antibody technology, biologic therapeutic, heavy chain antibody, IgNAR, shark, single chain binding domain
Abbreviations: CDR, complementarity-determining region; HV, hypervariable region; IgNAR, immunoglobulin new antigen
receptor; IgNAR V domain, variable domain of IgNAR; mAbs, monoclonal antibodies; scFv, single chain variable fragment;
VL, variable domain of the light chain; VH, variable domain of the heavy chain; VHH, variable domain of camelid heavy chain
antibodies; vNAR, variable domain of IgNAR
In addition to antibodies with the classical composition of
heavy and light chains, the adaptive immune repertoire of
sharks also includes a heavy-chain only isotype, where antigen
binding is mediated exclusively by a small and highly stable
domain, referred to as vNAR. In recent years, due to their high
afﬁnity and speciﬁcity combined with their small size, high
physicochemical stability and low-cost of production, vNAR
fragments have evolved as promising target-binding scaffolds
that can be tailor-made for applications in medicine and
biotechnology. This review highlights the structural features of
vNAR molecules, addresses aspects of their generation using
immunization or in vitro high throughput screening methods
and provides examples of therapeutic, diagnostic and other
biotechnological applications.
Introduction
Today, biological entities are one of the main drivers of the
pharmaceutical industry as exemplified by their current and pre-
dicted market growth rates, which substantially exceed those of
the overall sector. Within this group of biologic drugs, monoclonal
antibodies (mAbs) are the highest selling class, followed by hor-
mones, growth factors and then fusion proteins.1,2 The high speci-
ficity for a cognate antigen combined with Fc-mediated immune
effector functions have underpinned the success of antibodies as
effective tools for medical applications. With »40 antibodies
marketed and hundreds of mAbs in clinical development, the ther-
apeutic and economic value of mAbs is evident.1,3-5 Antibodies are
structurally complex, large hetero-tetrameric proteins that consist
of 2 heavy chains and 2 light chains (Fig. 1A). The 2 identical
antigen-binding sites, i.e., paratopes, are composed of one variable
domain of the light chain and one variable domain of the heavy
chain, respectively. However, under certain circumstances the ther-
apeutic and diagnostic efficacy of antibodies might be limited due
to inherent attributes, e.g., structural complexity, large size. The
paratope of conventional antibodies can be restricted in its ability
to access certain epitopes, e.g.,, recessed cryptic epitopes, active
sites of enzymes.6-8 Furthermore, the mobility, i.e., tissue penetra-
tion, of classical antibody molecules is constrained by their large
size.9 For in vivo tumor imaging purposes, the slow blood clear-
ance of conventional antibodies poses a problem due to their
extended plasma half-life.10 Slow tumor penetration as well as
nonspecific uptake by healthy tissues may represent further draw-
backs of conventional antibodies in molecular imaging.11-14 To
address these issues and to increase the overall therapeutic efficacy,
next-generation-antibodies, antibody fragments and non-immuno-
globulin based protein scaffolds have been engineered and devel-
oped, as extensively described elsewhere.15-24
Camelids and the cartilaginous fish possess natural antibodies
composed only of heavy chains (Fig. 1B and 1C).25,26 The anti-
gen binding site is formed by only one single domain, referred
to as VHH and vNAR, respectively. Due to an increased fre-
quency for polar and charged amino acids at the solvent-
exposed regions corresponding to the hydrophobic VH-VL
interface of conventional antibodies, vNAR and VHH domains
are highly soluble.27 Antigen‑binding domains of heavy chain
only antibodies (HCAbs) combine most of the beneficial fea-
tures of non-immunoglobulin-based protein scaffolds, e.g.,
small size, high stability, coupled with the advantageous charac-
teristics of classical antibody molecules, most strikingly the feasi-
bility to generate highly specific and high-affinity binders
through immunization.6,28
Even more interestingly, HCAbs naturally complement the
conventional repertoire of the aforementioned species. Whereas
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classical antibodies usually have planar or concave antigen bind-
ing sites, vNAR- and VHH-domains possess a wide variety of
additional (in the case of vNARs) and different loop structures.
This leads to a drastically expanded repertoire of available para-
topes capable of accessing and binding to more cryptic epitopes
and catalytic clefts of enzymes that are intractable to classical
antibodies.29-31 Hence, vNAR and VHH domains could add
considerable value to the therapeutic development pipeline by
broadening the range of druggable targets.
While camelid VHH domains have proven to be successful in
early phase clinical trials,32 the engineering of vNAR domains for
biomedical applications is at an earlier stage. However, significant
progress demonstrating the therapeutic utility of these domains has
been made in the last years. The purpose of this review is to summa-
rize the research conducted to date of IgNARs, placing the emphasis
on recent progress of the development of vNAR domains for thera-
peutic, diagnostic and other biotechnological applications.
The New Antigen Receptor
The cartilaginous fish (sharks, rays, skates and chimaeras)
express 3 different isotypes of antibodies, IgM, IgNAR and
IgW.33,34 Recent analysis of the genome of African coelacanth,
Latimeria chalumnae indicated that IgM was absent in this species,
while IgW was present, supporting the notion that IgW is a pri-
mordial immunoglobulin class.35,36 IgNAR was first identified in
the serum of the nurse shark (Ginglymostoma cirratum) in 1995 by
Flajnik and co-workers.26 It is a homodimer of heavy chains
devoid of light chains. Each chain of the secretory form consists of
one variable domain followed by 5 constant domains, the last 4
being homologous to IgW constant domains.37 Serum IgNAR
levels range from»0.1 mg/ml to 1 mg/ml.38
Based on atomic resolution structural data as well as small-angle
X-ray scattering, Buchner and coworkers were able to develop a
structural model of the complete IgNAR molecule (Fig. 1C).39
Within the molecule, domains C1 and C3 of each chain cause
dimerization of IgNAR.Despite the lack of a canonical hinge region,
the variable domains are spaced sufficiently wide for binding multi-
ple epitopes, facilitated by the wide angle of the C1 dimerization
interface. A small angle between both C3 domains induces the for-
mation of a narrow stalk for the IgNAR molecule. However, the
flexibility of the stalk is induced by a disulfide-bridged linker that
connects domains C3 and C4. The heavy chain-only molecule is
kinked approximately in the middle of the molecule, at the location
Figure 1. Structural features of intact IgG (A), camelid hclgG (B), and shark IgNAR (C) antibody formats shown as surface representation (top) as well as
ribbon and schematic representations (bottom). Individual domains are colored as indicated in the schematic representation; hinge regions are colored
yellow; glycans not shown. (A) IgG model is based on pdb entry 1IGT.95 (B) Model of hclgG was generated by molecular replacement based on pdb
entries 1IGT (for Fc region) and 1IEH (for VHH domain).95,96 1IEH was aligned to the CH1 domain of 1IGT with YASARA structure.97 After deletion of absent
domains (VL, CL, VH, and CH1), the VHH section was connected to the Fc region via a short camelid hinge sequence (see Hamers-Casterman et al.).25
Then, a 2-step energy minimization using YASARA2 force ﬁeld was conducted to yield the depicted structure. (C) Coordinates of intact IgNAR including
the hypothetical structure of IgNAR C5 domain were generously provided by Prof. Dr. Michael Sattler and Dr. Janosch Hennig (see Feige et al.).39 Picture
rendered with POV-Ray (www.povray.org/).
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of the flexible linker, causing its characteristic shape. Whether any
effector functions are mediated by the constant region of IgNAR is
currently unresolved.6 Finally, it is important to note that the struc-
ture of C5 shown in Figure 1C is completely hypothetical. This is
due to a lack of structural data on this domain, which does not
exhibit a fold, neither as isolated recombinant protein nor within a
C4-C5 construct.39
Absence of a Light Chain Partner
The homodimer IgNAR displays several unique features that
are responsible for the inhibition of a potential light chain pair-
ing. At the typical VH-VL interaction site, there is poor conserva-
tion of residues that mediate this association in mammals.40
Instead these typically hydrophobic amino acids are frequently
replaced by polar or charged residues.27 For classical antibodies,
a special mechanism ensures the formation of heavy- and light-
chain pairing. In the endoplasmic reticulum, the heavy chain is
trapped by an Ig-binding protein (BiP) via interaction with the
CH1 domain. For the release, a light chain must displace BiP,
and, consequently, only heavy- and light-chain paired antibodies
are secreted.27,41 Flajnik and coworkers hypothesized that during
evolution, a vNAR-D-J cluster recombined with an IgW cluster
in a way that the IgW cluster lost its V-D-J segments and the first
C exon.42 Indeed, the C1 domain of IgNAR is somewhat similar
to the CH2 domain of IgW and may be derived from this
domain.43 BiP- and L-chain-interactions sites are consistently
missing in the C1 domain of IgNAR, as elegantly reviewed by
Flajnik and colleagues.27
The Variable Domain of IgNAR – Structural Features
The variable domain of the New Antigen Receptor shows
homology to the T-cell receptor (TCR) Va and also is found as a
variable domain in the NAR-TCRd.44 It also displays sequence
homology to immunoglobulin Vk domains, whereas structurally
it is related to Va, Vl, and VH domains.
30 The evolutionary rela-
tionship of IgNAR and TCR and their therapeutic potential was
recently reviewed.45 Moreover, since vNAR domains share struc-
tural features of cell adhesion molecules, it was suggested that
IgNAR evolved from a cell-surface receptor, clearly distinguish-
ing it from VHH, which evidently arose from an IgG line-
age.27,46 vNAR belongs to the Ig superfamily, and accordingly it
has a b-sandwich fold. However, compared to mammalian V
domains, this fold only consists of 8 instead of 10 b-strands due
to the deletion in the framework2-CDR2-region (Fig. 2).
With a molecular mass of »12 kDa, the vNAR domain is the
smallest antibody-like antigen binding domain in the animal king-
dom known to date.6,30 As a consequence, contrary to mammalian
variable domains, vNAR domains have only 2 complementarity
determining regions CDR1 and CDR3 (Figs. 2, 3). The diversity of
the primary vNAR repertoire is predominantly found in CDR3.
High rates of somatic mutation after antigen contact are observed in
CDR1, at the CDR2 truncation site, where the remaining loop
Figure 2. Comparison of VH (left; from pdb entry 1IGT) and vNAR (right, from pdb entry 2COQ) binding domains depicted as ribbon representation as
well as an overlay of both structures (middle).31,95 CDR1 and CDR3 are shown in gray. Two b strands and CDR2 of the VH domain are highlighted in
orange. These structural elements are absent in the vNAR domain which possesses HV2 and HV4 (both highlighted in blue), instead. Disulﬁde bonds are
shown as yellow sticks. Picture rendered with POV-Ray (www.povray.org/).
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forms a belt-like structure at the bottom of the molecule, and in a
loop that corresponds to HV4 in TCRs. Accordingly, these muta-
tion-prone regions have been named HV2 and HV4, respectively
(Fig. 2).47 Indeed, it was shown that somatic mutations within HV4
can contribute to antigen binding.48
Despite having a reduced number of possible antigen binding
loops (4 across a single chain) compared to conventional antibod-
ies (6 loops across 2 chains), vNAR domains bind antigens with
surprisingly high affinities.49,50 Even from primary repertoires,
where antigen binding is solely mediated by CDR3, vNAR mole-
cules can be obtained against a given antigen with affinities in the
low nanomolar range.48,49 The highest recorded affinities for
vNAR domains, however, have been observed after
immunization with an anti-albumin
binding domain, achieving picomolar
levels of affinity.50
Based on the number of non-canonical
cysteine residues, which are not found in
classical variable domains, vNAR mole-
cules have been categorized into 4 types
(Fig. 3).30,31,48,51,52 The classical Ig
canonical cysteines, which stabilize the
immunoglobulin fold via a disulfide-
bond, are common to all types. Type I var-
iable domains carry extra cysteines in
framework regions 2 and 4, and, conse-
quently, an even number of partner cyste-
ine residues in CDR3. The determination
of the crystal structure of a type I vNAR in
complex with lysozyme revealed that both
non-canonical framework cysteines each
form disulfide-bonds with those of
CDR3, causing this loop to be held tightly
into the direction of HV2.30 Thus far,
type I variable domains of IgNAR have
only been identified in the nurse shark,
Ginglymostoma cirratum.6
Type II domains differ from type I by
means of an additional cysteine in
CDR1 and in CDR3, respectively,
resulting in an intra-molecular disulfide
bond that brings both loops in close
vicinity. However, it lacks both cysteine
motifs that anchor CDR3 to the frame-
work in type I vNAR. As a consequence,
the CDR3 region forms a protrusive
‘finger-like’ structure that is predisposed
to binding into pockets or grooves, e.g.,
the active site of enzymes.31 According
to this, it has been shown for both types
that active site clefts can be penetrated
by the antigen binding loops.30,48
Another type, termed type III, is
expressed in neonates at high frequen-
cies.31,51 Akin to type II domains, this
isotype is characterized by an additional
non-canonical cysteine in CDR1 and CDR3, respectively. How-
ever, in contrast to type II, type III domains comprise a restricted
CDR3 diversity, highly similar in amino acid composition and
length as well as a conserved tryptophan residue in CDR1 posi-
tioned adjacent to the disulfide bridge between both loops. Based
on the limited CDR3 diversity it is tempting to speculate that
type III vNARs evolved as a consequence of exposure to a com-
mon pathogen in early development of sharks or that it may play
a role in regulatory processes during the development of the
shark’s immune system.6,31,51
Type IV domains differ from all described vNAR types in that
they lack non-canonical disulfide bonds as found in all other
vNAR types.50,52 Therefore, the topology of the paratope of type
Figure 3. Different types of IgNAR V domains. Variable domains are categorized based on the pres-
ence or the absence of non-canonical cysteine residues (black dots). Canonical cysteine residues
(white dots) and disulﬁde bonds (connecting lines), conserved tryptophan (W) as well as complemen-
tarity determining regions (CDR) and hypervariable loops (HV) are shown in their relative positions.
Ribbon presentations of vNAR domains are depictions of pdb entries 1SQ22 (type I),30 2COQ (type
II),31 and 4HGK (type IV)52 as well as a modeled type III structure based on 2COQ. The latter was gener-
ated via homology modeling using YASARA structure.97 First, vNAR residues of 2COQ were changed
to match a reported type III sequence (AAM76948 from Streltsov et al.).31 Then, side chain geometries
were optimized followed by a 2-step energy minimization using the YASARA2 force ﬁeld.97
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IV variable domains is more flexible and not physically con-
strained. Type IV domains are also referred to as type IIb, accord-
ing to Streltsov et al. and Liu et al.46,53 In addition, type IV
domains with an invariant tryptophan residue in CDR1, similar
to type III, have been identified.54 Besides type III, all types of
the vNAR domain give rise to high-affinity binders.30,48,50,55
Diversiﬁcation of the IgNAR Repertoire
In mammals, antibody diversity is generated by a process
referred to as V(D)J-recombination. During B-cell development,
one variable (V) segment, one diversity (D) segment and one
joining (J) segment are randomly rearranged from a multitude of
gene segments of the immunoglobulin heavy chain gene cluster
to encode the VH domain, which is fused to a gene segment
encoding a constant domain.27 Similarly, for light chain genera-
tion, one V segment and one J segment are selected by chance
from a pool of gene segments to produce the variable domain of
the light chain that is fused to a CL gene. Diversity is further
expanded in a process called junctional diversification through
imprecise segment joining.56 An additional layer of diversity is
introduced by the random arrangement of the heavy chain and
light chain to complete the expression of the antibody molecule.
As IgNARs are devoid of light chains, they lack H-L combina-
torial diversification. Correspondingly, one would expect a dra-
matically restricted primary repertoire. However, this lack of
diversification process is at least partially compensated through
the diversity achieved within the CDR3 region. Whereas mam-
malian antibody genes are organized in the translocon-format,
shark antibody genes are exclusively arranged in the cluster-orga-
nization (Fig. 4).6,30,42,48 Nurse sharks comprise 4 IgNAR gene
clusters, though only 2 are expressed in adult life, one encodes
type I and one encodes type II IgNARs.30,48 Each IgNAR cluster
comprises one V segment, 3 D segments and one J segment and
a single set of C segments. Rearrangement occurs solely within
this cluster resulting in a VD1D2D3J assembly. Hence, 4 rear-
rangement processes generate the complete vNAR domain. How-
ever, the order of rearrangements remains to be determined.42
The interfaces between the V segment, the 3 D segments and the
J segment encode for CDR3. Consequently, diversity in both
sequence and length of the primary repertoire is nearly entirely
found in CDR3.51,57,58 Extensive junctional diversification
through N-region addition, P-nucleotide addition, trimming
and D-region rearrangement further expands the heterogeneity
of the primary repertoire of IgNAR.6,30,42.59 The type III gene
cluster represents an exception within the recombination process.
As a result of the fusion of the D1 segment and the D2 segment
in the nurse shark, only 3 rearrangement events occur, explaining
the restricted diversity of this type. In contrast to this, in the
spiny dogfish the type III IgNAR clusters are not partially germ-
line-joined, indicating that germline-joining of Ig clusters might
be a species-specific event.60
Sharks do not possess conventional germinal centers. Never-
theless, the initial combinatorial diversity, which is mainly
restricted to CDR3, is further expanded by extensive somatic
hypermutation in an antigen-driven manner, with mutations
clustering to the CDRs.57 The mutational pattern and frequen-
cies of this process are similar to that of mammalian immunoglo-
bulins with a bias for transitions over transversions. The
mechanism favors the serine codon AGC/T as a hotspot for
mutations and most of the changes are base substitutions. Sur-
prisingly, base changes often occur in tandem, particularly in
mutational hotspots and palindromic repeats.58 It was first shown
Figure 4. Translocon arrangements of immunoglobulin genes in higher vertebrates and cluster conﬁguration of IgNAR genes of cartilaginous ﬁsh. In the
translocon organization there are many variable (V) segments upstream of many diversity (D, only for heavy chains) and joining (J) segments that recom-
bine randomly to encode the variable domain of the heavy chain or the light chain. IgNAR genes (like all Ig genes of the cartilaginous ﬁsh) are organized
in the cluster conﬁguration. Each cluster contains for the variable domain one V segment, 3 D segments and one J segment. Recombination occurs exclu-
sively within one cluster. H, heavy chain loci; L, light chain loci, C, constant region.
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by Flajnik and coworkers, that after immunization, somatic
mutations promoted an incremental increase in affinity, giving
clear evidence for in vivo affinity maturation in sharks.30,38,47-49
Furthermore, they demonstrated that HV4 is prone to somatic
mutations and, even more interesting, these mutations can be
involved in antigen binding.48
Consistent with the structure of type I and type II IgNARs
(Fig. 3), mutations are favored in CDR1 for type II vNARs and
in HV2 for type I vNARs.27,30 It is hypothesized that those
mutations could either directly contribute to antigen binding or
they could indirectly have an effect on the paratope such that
they stabilize and influence the conformation of the antigen-
binding CDR3.
Selection of Antigen-Speciﬁc vNAR Domains
From Shark Immune Repertoires
Antigen-specific vNAR domains have been generated from the
immune repertoire of a number of different shark species, includ-
ing the nurse shark,49 the wobbegong shark,55,61 the spiny dog-
fish,50,53,62 the banded houndshark63,64 and the bamboo shark.65
Target-specific clones are generally isolated using different dis-
play technologies, such as phage display49,55 or ribosome dis-
play.66 We recently showed that antigen-specific vNAR
molecules can also be selected using yeast surface display as plat-
form technology.65 A potential advantage of yeast surface display
over the above mentioned display technologies is the amenability
of single-cell online and real-time analysis, as well as subsequent
characterization of individual library candidates in terms of speci-
ficity, affinity and stability.67,68
There are several distinct strategies for library establishment.
Binders can be selected from immunized sharks,49,50 from the na€ıve
shark repertoire,53 or from a synthetic vNAR library,55,69 where the
vNAR molecule serves as a scaffold with randomized loops and
from semi-synthetic repertoires. Here, additional diversity is
included through the randomization of one or more antigen-bind-
ing loops.62,70 For the most part, immunization is the preferred
route to obtain high affinity binders. An additional advantage of
immunization is that sharks are evolutionary very distant to humans.
This greatly reduces the likelihood of immune tolerance that would
reduce the induction of target-specific responses when antigens are
well conserved across species. Consequently, antigen-specific vNAR
molecules have been generated with impressive affinities against a
multitude of different targets via immunization.49,50,71,72 However,
the process of immunization of sharks is protracted compared to
standard mammalian protocols, and not every species tested has
proven successful.50,73 For instance Dooley et al. and also our group
(unpublished results) were unable to detect an antigen-specific
IgNAR response after the immunization of the small spotted cat-
shark, Scyliorhinus canicula.74
Antigen-specific vNAR fragments have also been isolated from
non-immunized libraries against a plethora of different targets,
including viral targets, cytokines, proteins involved in cancer and
arthritis and toxins.53,62,64,65,70,75,76 Table 1 illustrates vNARs
selected against therapeutically relevant targets from immunized
and non-immunized origins (Table 1). Surprisingly, binders
selected from such libraries often show good affinities to their tar-
get.61,62,75,76 Nonetheless, when higher affinities are required,
vNARs can be optimized using in vitro affinity maturation. In
this respect 3 different methodologies have been established.
Nuttall and co-workers were able to improve the affinity for an
AMA1-specific IgNAR V domain using error-prone PCR result-
ing in »10-fold enhanced affinity.76 In a more recent approach,
the same group employed a mutagenesis system dependent on
low fidelity RNA polymerase from Qb bacteriophage to intro-
duce diversity into IgNAR antibody libraries for affinity matura-
tion. With this novel strategy they were able to select mutated
vNAR molecules with a more than 20-fold enhanced affinity
compared to the wild type clone.66
We recently established a stepwise in vitro affinity maturation
methodology for the generation of high affinity binders derived
from shark vNAR domains. To this end, binders were selected
from a library in which CDR3 was totally randomized using
yeast surface display. Affinities of binders were significantly
improved by CDR1 diversification and sublibrary screening,
resulting in enhanced molecules with affinities in the low nano-
molar range.65 Interestingly, this method resembles the natural
strategy of the immune system of nurse sharks to generate high
affinity antibodies.
Therapeutic and Diagnostic Attributes of vNAR
Domains
The tremendous diversity found at the sequence-level of the
CDR3-loop of IgNAR, as well as the multiplicity of the struc-
tural topologies formed by the antigen-binding site of the vNAR
domain (Fig. 5), render IgNARs promising alternatives to
Table 1. Published vNAR domains against disease related targets. Adapted
from ref. 54
Target Potential Application Reference
VHSV Anti-viral 64
TNF-a Endotoxic shock 98
HSA Half-life extension 50
HBeAg of HBV Anti-viral 75
Ebola virus Immunodiagnostic 72
Cholera toxin Biosensor 53
Staphylococcal
enterotoxin B
Sensors 62
Ricin Sensor 62
Botulinum toxin Sensor 62
AMA1 Malaria diagnosis 66,76
EpCAM Cancer diagnostic & therapy 65
HTRA1 Arthritis therapy 65
EphA2 Cancer diagnostic & therapy 65
IL-8 Anti-inﬂammation unpublished results
VHSV: Viral hemorrhagic septicaemia virus, TNF: Tumor necrosis factor,
HBeAg: Hepatitis B e antigen, HBV: Hepatitis B virus, HSA: Human serum
albumin, AMA1: Malarial apical membrane antigen-1, EpCAM: Epithelial cell
adhesion molecule, HTRA1: Human serine protease HTRA1, IL-8: Interleukin
8.
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conventional antibodies.30,31,48 As described above, the different
types of vNAR domains form, if any, a very diverse set of disul-
fide-bridges. Consequently, antigen-specific clones can be
selected from a very large, unprecedented repertoire of different
loop structures.77 Moreover this unique paratope-architecture of
shark domains seems to be predisposed to target clefts of the anti-
gen, whereas recessed epitopes are usually not antigenic for con-
ventional antibodies.27,31,46,78 Indeed, it has been shown that the
active site of enzymes and clefts can be targeted by vNAR
domains.30,39,48
Above all, vNARs exhibit many additional properties that ren-
der them interesting for diagnostic and therapeutic applications.
It has been demonstrated that vNARs are extraordinarily stable
proteins,49,53,62,69,72 which is probably a consequence of the
harsh physiological environment - the blood of sharks contains
350 mM urea - those molecules are exposed to.54 The superior
thermal stability and tolerance to irreversible thermal denatur-
ation compared to scFv- and mAb-formats was elegantly demon-
strated by Lonsdale and colleagues, as well as by Goldman and
coworkers.53,79 Even type IV domains, which lack the non-
canonical loop stabilizing disulfide-bond, show superior thermal
stability, with Tm values that for the most part exceed 70C.65
In contrast to this, scFv fragments often show Tm values in the
range between 50C and 65C.80,81 However, Tm may some-
times be below 40C, requiring optimization of their thermal sta-
bility.82,83 Concordantly, it has been shown that the C2 and C4
domains of IgNAR are very stable. Buchner and coworkers were
able to identify structural elements that contribute to their high
Figure 5. Examples of CDR3 variability in vNAR domains depicted in ribbon representation. (A) Short loop (type IV, pdb entry 4HGK).52 (B) Large loop
with one disulﬁde constraint (type II, pdb entry 2COQ).31 (C) Highly constrained loop tethered by 2 cystine motifs (type I, pdb entry 1SQ2).30 (D) Extended
CDR3 forming an a- helical motif (type II, pdb entry 2I25).48 (E) Extended CDR3 forming a 2-stranded b-sheet (type IV, pdb entry 2Z8V).78 (F) Extended
CDR3 incorporating an amyloid-b p3 fragment (type IV, pdb entry 3MOQ).94 (G) Overlay of structures A–F. Disulﬁde bonds are shown in yellow. Picture
rendered with POV-Ray (www.povray.org/).
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stability. Compared to mammalian constant domains, C2 and
C4 domains of IgNAR contain an additional salt bridge and an
extended hydrophobic core. The transfer of these key elements of
enhanced stability to a human antibody domain improved its sta-
bility significantly.39
The inherent small size of the IgNAR V domain is an addi-
tional therapeutic and diagnostic attribute. It can be hypothesized
that this property leads to a greater mobility with reference to tis-
sue penetration. Especially for in vivo imaging, where a high con-
trast to background ratio is crucial, this feature is beneficial, due
to an advantageous pharmacokinetic profile, i.e., a much shorter
residence time in the blood compared to classical antibodies.10
Furthermore it is assumed that the small molecular weight of the
vNAR domain implicates the opportunity to target epitopes oth-
erwise only accessible to small molecules.6
Re-Formatting of vNAR Domains
The simple single chain molecular architecture of vNAR
domains affords the benefit of multiple re-formatting opportuni-
ties to tailor the final product for purpose. Many formats have
been successfully proven, including monomeric, dimeric and tri-
meric (binding more than one target) in addition to Fc-based for-
mats, with all demonstrating the inherent flexibility of these
domains.50,52,54,84
The small size of vNAR domains contributes to rapid renal
clearance in vivo and represents a major drawback when non-
imaging applications such as tumor-targeting are required. How-
ever, reduced size can be advantageous with regard to tumor pene-
tration and ultimately the right format for the individual
application needs to be determined. Fast glomerular filtration can
be circumvented by multimerization of single vNAR domains, as
has been shown by M€uller et al.50 Their investigations covered the
N- as well as C-terminal fusion of a naїve vNAR domain with an
anti-human serum albumin (HSA) vNAR originating from an
immunized shark and isolated via phage display.85 The fusion
constructs retained high-affinity binding to HSA and exhibited sig-
nificantly increased in vivo half-lifes compared to their unconju-
gated parental domains. The size of such dimeric formats is in the
range of 25 kDa, and, compared to other antibody fragment for-
mats such as scFvs, achieves double the binding site capacity while
attaining increased affinities toward demanding, cryptic epitopes,
which is a hallmark of vNAR proteins owing to their unique
topology. In addition to dimeric fusions, a trimeric construct com-
prising the naїve vNAR domain at both termini of the anti-HSA
vNAR displayed improved pharmacokinetics in in vivo studies in
different species.50 In another study conducted by Nuttall and col-
leagues, several approaches for the generation of bivalent shark
antibodies with enhanced functional affinity were investigated.84
Best affinities were obtained through C-terminal covalent or
domain mediated linkages.
As has been shown extensively for rodent mAbs, there is a
plethora of rational as well as empirical humanization strategies
available to reduce immunogenic responses caused by animal-
derived immunoglobulins.86-90 Rational design and the grafting
of CDR loops of a xenogenic antibody onto a suitable human
scaffold exhibiting a similar sequence has culminated in the
development of several blockbuster pharmaceuticals routinely
used in the clinic (e.g., trastuzumab, bevacizumab).91
The sequence identity of the IgNAR V domain with mamma-
lian VH regions falls as low as 25%.49 In order to minimize the
immunogenic potential of vNAR domains, Kovalenko and cow-
orkers were able to engineer the aforementioned anti-HSA shark
vNAR domain50 by converting more than half of the framework
amino acids to those of the human germline VK1 sequence
DPK9.52 This sequence bears the highest structural resemblance
to the corresponding vNAR domain, and concomitantly repre-
sents one of the most stable human frameworks for downstream
development. Determination of the binding constants of human-
ized vNAR variants yielded antigen affinities similar to those of
the parental construct (14.8 nM vs 13.6 nM for the parental
molecule). The opposite approach, i.e., starting with a structur-
ally related human VH domain and converting that to a vNAR-
like domain by clipping the CDR2 region, extending CDR3 and
introducing stabilizing residues and additional disulfides, may
also be a viable alternative as already shown for the camelization
of human VH domains.92 To enhance the expression of human-
ized vNARs in mammalian cells, they were C-terminally fused to
human Fc domains.52 This conjugation strategy can also contrib-
ute to the formation of dimers due to the interactions of 2
vNAR-Fc conjugates at the respective human constant domains.
Fusions to human Fc, besides increasing the overall molecular
weight and thus counteracting early renal clearance, can elicit in
vivo immune effector functions and ultimately intensify the
immune response via antibody-dependent cellular cytotoxicity
and complement-dependent cytotoxicity. According to Kovaleva
et al., the humanized IgNAR V domain variant showed negligi-
ble immunogenicity in dendritic cell assays.54 Notably, also no
significant immunogenic effects were observed after subcutane-
ous application of the parental, non-humanized anti-HSA vNAR
in rodents and non-human primates.50,54 However, it remains to
be scrutinized more meticulously how these proteins will behave
when administered to patients in the scope of clinical trials.
Besides diagnostic and therapeutic applications, vNAR
domains, due to their small size, high stability and their ability to
sustain repeated cycles of unfolding and folding are also promis-
ing biomolecules for biotechnological applications to serve for
example as high affinity capturing agents for purification of bio-
molecules or as tools for diagnostic applications. It was recently
shown that vNAR fragments can be coupled covalently and site-
specifically onto crystalline nanocellulose that serves as a protein-
capturing nanoscaffold.93 This evidence, coupled with the
demonstrated stability and flexibility of vNAR domains, would
predict more biotechnological applications can be expected to
show up in the next years. Additionally, the vNAR domain can
be utilized to gain information about pathological processes that
at present are not completely understood. This was exemplified
by Nuttall and colleagues, who grafted parts of the Ab-peptide
involved in Alzheimer’s disease into CDR3 of a vNAR domain,
and thus solved the crystal structure of the amyloid-b p3 frag-
ment (Fig. 5F).94
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Conclusion
Antibodies are essential molecules for biomedical and biotech-
nological applications. As described above, shark IgNARs differ
greatly from conventional antibodies in many respects. Because
of their unique structural features, these molecules have emerged
as promising candidates for therapeutic, diagnostic and biotech-
nological applications. One striking example is that vNAR
domains may complement classical antibodies in terms of drug-
gable antigens. IgNAR V domains possess the potential to access
cryptic and recessed epitopes that are usually not antigenic for
conventional antibodies, e.g., hydrophobic clefts, active sites.
However, this has only been shown for targeting the active site of
lysozyme, as well as for targeting the hydrophobic cleft of
AMA1, and therefore requires further exploration.30,48,78 Their
small size, high stability and the feasibility to re-format those
molecules are additional desirable attributes. During the last
years, constant progress on shark IgNAR research has been made.
Related to this, vNAR domains targeting a plethora of therapeu-
tically relevant antigens were generated and several methodolo-
gies for affinity-maturation of target-specific vNAR domains, as
well as for re-formatting, e.g., humanization, multimerization,
have been established. Moreover, a structural model of the com-
plete IgNAR molecule revealed deeper insights into the extraordi-
nary shape, stability and mode of action of this unique binding
domain. Information gained from this might pave the way for
the next generation of classical antibody variants showing
improved stability. Fundamentally, it can be expected that this
exceptional molecule, which evolved several hundred million
years ago, might add value to the continuously evolving and
exciting field of biologic drug development. Finally, it needs to
be emphasized that, in view of future clinical applications, the
immunogenic potential of vNAR domains requires further in
depth investigation.
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